Aerie ROCKETS On Glaucoma Data
This article was originally published in Scrip
Aerie Pharmaceuticals Inc. has reported positive results from its second Phase III trial for Rhopressa (AR-13324), which is being tested to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The news sent the company's share price soaring by almost 70% (Sep. 17), and Aerie expects to file its NDA for Rhopressa in mid-2016.
Register for our free email digests: